leisure time -WSS

leisure time

author：explore 2025-09-30 00:49:37 - browse：2

Pfizer plans to exit a major biotechnology industry trade association. Cindy Ord/Getty Images for Pfizer/BioNTech

WASHINGTON — Pfizer has decided to leave the Biotechnology Innovation Organization, according to two sources familiar with the planning.

The departure is a blow to BIO, which represents members ranging from small biotech startups to massive pharmaceutical companies. The group on Tuesday announced its new CEO, rare disease advocate and biotech executive John Crowley.

“The economic situation for the industry is difficult indeed and we of course are disappointed that any company would be forced to take a break from its BIO membership. We certainly hope that when economic conditions improve, we can welcome those companies back and welcome new members to join us as well, but it in no way affects our mission of protecting patients and medical innovation in the United States,” said BIO’s Chief Public Affairs and Marketing Officer Rich Masters. Masters said he wouldn’t comment on the status of any particular member.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

focus

WSS

Bill would stop addiction treatment from triggering child abuse inquiry

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

Phenylephrine and the overlooked value of the placebo effect

Liquid biopsy for lung cancer is launched by Delfi

Teach medical students about patients with intellectual disabilities

Supreme Court wrestles with OxyContin maker's bankruptcy deal

hotspot

leisure time

Wikipedia

Medical leaders decry Supreme Court decision on affirmative action

Leukemia patients are helped by Syndax's new type of therapy

Supreme Court strikes down use of affirmative action

Chemotherapy drug shortage eases slightly but still widespread

New air purifier tech could be key to improving indoor air quality

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

United colonoscopy coverage change 'may cost lives,' doctors say

Colorectal cancer study finds potential in overlooked immune cell

DIEP, the 'gold standard' of breast reconstruction, is under threat

Patients' immediate access to test results puts radiologists in a bind

hotspot

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

Why age limits for politicians are a terrible idea

Histogen: Failed biotech offers rare public look inside

Pharma patents targeted by Biden in move to slash drug prices

FDA panel signals lack of confidence in Amgen cancer drug data

FDA panel signals lack of confidence in Amgen cancer drug data

leisure time

hotspot

focus

entertainment